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Abstract
A chronically elevated vasopressin level has been associated with an impaired glucose
regulation system in humans. A recent study in patients with diabetes suggested that low
water intake is associated with impaired glucose regulation. The aim of this study was to
examine the effect of hypertonic saline infusion on glucose regulation in healthy females.
Thirty healthy, non-diabetic females performed a 2-h infusion followed by a 4-h oral glucose
tolerance test (OGTT). Every subject participated in two trials separated by one month, in a
counterbalanced order. Two trials were identical in the procedure, differing in the
concentration of saline infusion, with one trial being 3% NaCl (HYPER), another being 0.9%
NaCl (ISO). The HYPER trial led to an increase in plasma osmolality (time point 0 min,
305±0.91 vs. 287±0.61 mmol/kg, P<0.35), plasma volume expansion (16.69±1 vs. 9.72±
0.74 %, P<0.0001) and plasma copeptin (time point -90 min 7.16±1.07 vs. 3.37±0.3 pmol/l,
P<0.0001). Plasma glucose during the OGTT was greater in the HYPER trial. These data
suggest that the acutely induced cellular dehydration impairs the glucose regulation in healthy
females.
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Introduction
Low water intake has been reported to be associated with chronic diseases (Thornton,
2009). Osmoreceptors that exist in the central nervous system, detect the increase in plasma
osmolality, then signal to other parts of the brain to initiate the act of searching for drinking
water by intriguing thirst. (Arsenijevic & Baertschi, 1985). Low level of drinking water
activates these osmoreceptors in the brain and baroreceptors stimulate the hypothalamus to
liberate arginine vasopressin (AVP) into the bloodstream to reabsorb the water in the kidney
(Baylis, 1989). When osmolality is elevated, either plasma sodium or glucose levels might be
elevated due to the decrease of total body water (Thomas et al., 2008).
Elevated AVP is correlated with plasma osmolality and it has been reported to be
associated with the development of diabetes (Saleem et al., 2009). Furthermore, low insulin
sensitivity and high risk of developing T2DM have been demonstrated having an association
with high plasma copeptin level (Roussel et al., 2016). In a recent study, 565 subjects of a
3615 participants 9-year follow-up study became hyperglycemic and 202 developed diabetes,
of whom were drinking less than 0.5 L water a day, compared with other participants drinking
more than 0.5 L water a day, suggesting that water intake was inversely associated with
hyperglycemia (Roussel et al., 2011). Carroll and her colleagues (2015) found in a study,
where the relationship of plain water intake and type 2 diabetes risk was examined, that
higher water intake has a positive association in reducing the risk of type 2 diabetes (Carroll,
Davis, & Papadaki, 2015). Additionally, in a study by Stookey et al (2004), hypertonicity was
independently associated with an increased risk of developing diabetes. Their study further
suggested that hypertonicity magnified the effects of elevated glucose level so that
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individuals with hypertonicity and high plasma glucose level were four times more likely to
develop diabetes than those with elevated plasma glucose only (Stookey, Piper, & Cohen,
2013). It seems evident that associations of low water intake and metabolic syndromes were
found in studies discussed above.
Roussel and his colleagues (2016) found high plasma copeptin was associated with
reduced insulin sensitivity and an increased risk for IFG/T2DM in subjects investigated,
where the participants in the higher quartile of plasma copeptin level had significantly lower
insulin sensitivity (Roussel et al., 2016). In another study, AVP was determined to have an
association with increased risk of diabetes in older men, which suggests a potential role of the
AVP system in diabetes (Wannamethee et al., 2015). More studies show that not only there
exists an association between low water intake or high AVP and hyperglycemia, but there are
causality links between them. In a study that focused on determining the long-term influence
of plasma vasopressin concentration in a rodent model prone to metabolic syndrome,
researchers manipulated vasopressin levels in two opposite directions in lean and obese rats
groups in a 4-week period. Lean rats with high AVP level had higher fasting glycemia
compared to lean rats with normal AVP level. Conversely, utilizing an antagonist of AVP
receptor 1A reduced glucose intolerance in obese rats compared to control group, with fasting
insulin levels of 634±180 versus 1526±163 pmol/l, P<0.001 (Taveau et al., 2015). Another
study in humans with type 2 diabetes showed that low water intake impaired blood glucose
regulation probably due to cortisol responses (Johnson et al., 2017). AVP reduction through
water supplementation appears as an attractive candidate for intervention to preventing
diabetes and its cardiovascular complications (Mellander, 2016). Based on the existing
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literature regarding the role of AVP in glucose regulation, it is positive that AVP system plays
an important role in glucose regulation.
As suggested by previous studies that AVP is a small and unstable molecule, making it
difficult to measure; copeptin is a precursor molecule of AVP that is produced in same mole
amount with AVP in plasma, where it is very stable compared to ATP itself, thus it can be
chosen as an alternative marker measured (Morgenthaler, Struck, Alonso, & Bergmann,
2006). Therefore, copeptin reflects the release of AVP and can serve as a reliable surrogate
marker for circulating levels of AVP. One study analyzed copeptin baseline data from a
population from Malmo Diet and Cancer Study cardiovascular cohort during 1991-1994 and
conducted a follow-up experiment where 2064 subjects underwent an oral glucose tolerance
test. They found that increased copeptin predicted incident abdominal obesity, diabetes
mellitus, and microalbuminuria in diabetes individuals (Enhorning et al., 2013). Furthermore,
Enhorning and her colleagues (2015) conducted another study including both diabetes and
non-diabetes individuals; they found that copeptin could predict heart failure, coronary artery
disease and death specifically in diabetes patients, but not in the non-diabetes individuals.
We hypothesized that hypertonic saline infusion would induce cellular dehydration,
acutely raise copeptin levels and show an acute impairment of glucose regulation in healthy
lean and obese females. Therefore, combining previous studies and current knowledge gap,
the purpose of this study was to investigate the effect of elevated copeptin on glucose
regulation in obese and lean females.
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Methodology

Subjects

Thirty females with the absence of diabetes (HOMA-IR<6.5), not pregnant, aged
between 32-50 years old, were recruited in this study. Fifteen of them were overweight or
obese, with BMI 27.5-35 kg/m² and 36%-50.6% body fat, and 15 of them were lean, with
BMI between 18.5-22.5kg/m² and 25.4%-37.6% body fat.

Subjects inclusion criteria

Sedentary lifestyle, non-smoking within the past 6 months, no surgical operation on
the digestive tract, no cardiovascular diseases, and no medications impairing water balance.
All subjects recruited signed an informed consent prior to the initiation of any trial procedure.

Experiment design

The effect of cellular dehydration on glucose regulation was studied using osmotic
stimulation of AVP by hypertonic saline infusion followed by an oral glucose tolerance test
(OGTT). All the subjects had two trials separated at least by a week. In one trial the subjects
were infused with 3% NaCl (Baxter 3% Sodium Chloride Injection, USP), and in another
trial, the subjects were infused with 0.9%NaCl (Baxter 0.9% Sodium Chloride Injection,
USP). The hypertonic saline infusion was estimated to increase plasma osmolality from 285
to 300 mmol/kg, while isotonic saline infusion was infused to maintain osmolality at
euhydrated thresholds of 285 to 290 mmol/kg. Both experimental trials were kept identical
except for the difference in saline infusion concentration administered. Moreover, each
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subject performed the hypertonic or isotonic trial in a random, counterbalanced order. All
subjects performed both trials during their respective early follicular phase, approximately 16 days post menses onset to ensure low endogenous levels of estrogen and progesterone.
Subjects consumed a normal diet rich in carbohydrates for 3 days leading up to and refrained
from physical activity 24 h prior to each testing day. Dinner and 24h fluid intake pre-test day
were standardized while alcohol and caffeine consumption were prohibited.

Protocol

Subjects reported to the lab following 10 h of fasting. After providing a urine sample,
the subject remained seated for 30 minutes. An intravenous catheter (BD Angiocath
Antoguard 20GA 1.16 IN, 1.1*30mm) was placed in an antecubital vein and intravenous
infusion of either 3% NaCl or 0.9% NaCl commenced over a 120 minutes period at a rate of
0.1ml/min/kg of body weight, with blood samples being taken by technicians at baseline and
then following an interval of 30 minutes. After the initial 2 h saline infusion period, the
infusion line was removed from the catheter, which was flushed with an isotonic
saline/heparin mixture to prevent the intravenous line from clotting, and subsequently a stopcock (Medex 3-way stop-cock APV=0.5ml, Rx) was attached to allow for continuous blood
sampling in 30 min intervals at no discomfort for the participant. Then, subjects started the
OGTT that initiated with a 75 g glucose drink (Kosher Oral Glucose Tolerance Drink 75g)
ingestion. The OGTT lasted for 240 minutes, during which blood samples were taken, every
30 minutes. Urine sample collection was standardized upon initial arrival to confirm
hydration status for both trial days, at the end of the saline infusion and at the end of the
5

OGTT, while each participant was reminded to communicate urge for urination to the
technician for additional urine sampling as needed. Blood pressure was recorded by a manual
blood pressure cuff (Suntech Medical’s Clinical-Grade Orbit-K Blood Pressure Cuffs)
following each blood sampling. Whole blood samples were analyzed in triplicate to average
hematocrit and hemoglobin measurements via microhematocrit centrifuge (Unico Micro
Hematocrit Centrifuge, Model: C-MH30), reader (Damon/IEC Division Micro-Capillary
Reader) and UV spectroscopy (Thermo Scientific Genesys 10S UV-VIS Spectrophotometer)
respectively. Remaining whole blood was aliquoted into Lithium Heparin (Lithium heparin
(LH) 75 USP Units Blood Collection Tubes), EDTA (EDTA（K2E）10.8mg Plus Blood
Collection Tubes) and Serum separator tubes (SST Plus Blood Collection Tubes) respectively
and subsequently spun at 3000 rpm for 10 min. The supernatant was then removed from the
spun sample and aliquoted and stored at -80℃ for later hormonal analysis. 500µl of lithium
heparin plasma was taken for assessment of plasma osmolality via freeze point depression
(Advanced Instruments Model 3250 Osmometer). Urine samples were analyzed for specific
gravity via refractometry (ATAGO Clinical Refractometer Master-SUR/NM) and urine
osmolality via freeze point depression (Advanced Instruments Model 3250 Osmometer)
respectively.

Statistical analysis

Dependent variables measured were blood levels of insulin, glucose, and copeptin.
Further, plasma osmolality, hematocrit, and hemoglobin values were analyzed for
determination of plasma volume expansion and total plasma protein dilution in order to
6

confirm cellular de-/hydration of subjects. Statistical analysis was performed using JMP Pro
13.2.0. Between-condition differences for plasma osmolality, plasma sodium, Δ plasma
volume expansion, total plasma protein, glucose, insulin, and copeptin were assessed via twoway repeated measures analysis of variance with post-hoc contrast comparison.
The area under the curve for glucose and insulin was calculated to assess the actual
total exposure following OGTT administration. Significant α level was set at p<0.05. Results
described as means (SE).

Results

A total of 30 females completed the study. Plasma sodium was significantly higher
during the dehydrated condition starting from the time point -90 min. (euhydrated trial PNa:
136.64±0.34 mmol/L, dehydrated trial PNa:143.16±0.68 mmol/L, P＜0.0001, d=2.23); while
at the baseline (-120min), no significant difference in plasma sodium level between
conditions existed (euhydrated trial PNa: 135.7±0.3 mmol/L; dehydrated trial PNa:
136.3±0.41mmol/L, P＜0.247, d=0.30) (Figure 1.).
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Figure 1. Plasma sodium concentration during the trial. * denotes the statistically significant
difference between trials for the same time point.
In concert, plasma osmolality of the dehydrated trial was significantly higher than that of the
euhydrated trial from the time point -90 min(euhydrated trial POsmo: 285±0.63 mmol/kg;
dehydrated trial POsmo: 295.43±0.78 mmol/kg, P<0.0001, d=2.7); at the baseline (-120 min),
no difference existed between conditions (euhydrated trial POsmo: 284.22±0.65 mmol/kg;
dehydrated trial POsmo: 285.12±0.66 mmol/kg, P＜0.3527, effect=0.25) (Figure 2.).
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Figure 2. Plasma osmolality during the trial. * denotes the statistically significant difference
between trials for the same time point.
Furthermore, the difference of plasma copeptin between two conditions was
significant. Plasma copeptin level during the dehydrated trial was significantly higher than
during the euhydrated trial from the time point -90 min (euhydrated group PCopeptin:
3.37±0.3 pmol/L; dehydrated trial PCopeptin: 7.16±1.07 pmol/L, P<0.0001, effect=0.88) to
the end of the experiment; at baseline, no significant difference between two trials
(euhydrated trial PCopeptin: 3.64±0.36 pmol/L; dehydrated trial PCopeptin: 4.18±0.75
pmol/L, P=0.768, effect=0.16) (Figure 3.).

Figure 3. Plasma copeptin concentration during the trial. * denotes the statistically significant
difference between trials for the same time point.
The difference in change of plasma volume expansion was significant between trials
starting from the beginning of the experiment to the end (Figure 4.).
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Figure 4. Percentage of the delta of plasma volume expansion during the trial. * denotes the
statistically significant difference between trials for the same time point.
The total plasma protein content of dehydrated trial was significantly lower than that
of the euhydrated trial (mean difference between conditions is 0.308g/dL±0.016, 95%
confidence interval (0.277-0.339), p=0.0001) (Figure 5.).
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Figure 5. Total plasma protein concentration during the trial. * denotes the statistically
significant difference between trials for the same time point.
The difference of the serum insulin between two trials was not significant, except at
the time point 30 min during the OGTT period, where the euhydrated trial had a significantly
higher value than that of the dehydrated trial (euhydrated trial serum insulin: 383.86±7.9
pmol/L; dehydrated trial serum insulin: 223.14±4.1 pmol/L P<0.0001, effect=4.66). Besides,
at the time point 60 min, the comparison showed a trend of difference approaching
significance (euhydrated trial serum insulin: 451.02±8.34 pmol/L; dehydrated trial serum
insulin: 376.33±5.21 pmol/L, P<0.0734, effect=1.96) (Figure 6).
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Figure 6. Serum insulin concentration during the trial. * denotes the statistically significant
difference between trials for the same time point.
There was no significant difference in fasting glucose between two trials from the
beginning to the end of the experiment in terms of two-way ANOVA analysis (Figure 7).

Figure 7. Plasma glucose concentration during the trial. * denotes the statistically significant
difference between trials for the same time point.
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Nevertheless, further analysis of area under the curve found that the glucose levels were
significantly higher in the dehydrated trial compared to the euhydrated trial (Figure-8).

Discussion

This study tested the hypothesis that the saline infusion to the subjects would induce
cellular dehydration, elevate the level of copeptin, acutely impair the ability of glucose
regulation in healthy lean and obese females. Our results have shown that the 3% saline
infusion successfully induced cellular dehydration, elevated the level of copeptin, and the
glucose regulation was impaired in dehydrated trial.
Cellular dehydration. The data of plasma osmolality, plasma sodium, T protein, and
delta plasma volume expansion have demonstrated that 3% saline infusion to the subjects
indeed induced the cellular dehydration in the subjects of the dehydrated trial. Defining
cellular dehydration in human subjects requires all dataset mentioned above and reasons are
as follows. The osmolality threshold was defined earlier as extremes between 280-295
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mOsm/l by Feig and McCurdy (1977). Our results show that dehydrated trials had osmolality
higher than 295 mOsm/l from the time point -90 min till the end of the experiment(graph-2),
hence based on the defined threshold of the osmolality the dehydrated trial showed a sign of
an evident increase of osmolality compared to the normal daily range. Comparing dehydrated
trial with euhydrated trial, data also show a significant difference between two groups starting
from the time point -90 min. Therefore, the plasma osmolality of the dehydrated trial was
significantly increased by the 3% saline infusion in this study. But as suggested by Feig and
McCurdy (1977), the difference between hypertonicity and hyperosmolality cannot be
distinguished by clinical methods that measure plasma osmolality, which we used to measure
plasma osmolality in this study, so examining the plasma sodium to determine whether it is
hypertonic under hyperosmolality is necessary. Our results show that the dehydrated trial had
significantly higher plasma sodium starting from the time point -90 min till the end of the
experiment. Moreover, the plasma sodium of dehydrated trial exceeded the normal range of
135-142 mmol/l, starting from the time point -90 min. Both of the plasma osmolality and
plasma sodium followed a corresponding trend along the study. Combining the plasma
osmolality and plasma sodium data, it might be safe to say the dehydrated trial successfully
induced a hypertonic state in subjects. In addition to examining the plasma osmolality and
plasma sodium, we also examined the change of plasma volume expansion. According to
Feig and McCurdy (1977), there should be an extracellular volume expansion following the
ingestion of solutes, such as sodium. Our results show that the dehydrated trial had a
significantly higher change of plasma volume expansion during the experiment, starting from
time point -90 min. This might suggest that there was more water excreted from the cell to
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the plasma in the dehydrated trial. Furthermore, we measured the total plasma protein
concentration to corroborate this volume expansion. Our results show that the total plasma
protein concentration of dehydrated trial was significantly higher than that of the euhydrated
trial, supporting that there might be more water excreted from the cell to plasma so that the
total plasma protein concentration was diluted. Consequently, we could safely draw a
conclusion that dehydrated trial in our study achieved the cellular dehydration starting from
the time point -90 min to 0 min by infusion of 3% saline.
AVP/Copeptin. According to Thornton (2010), AVP regulates the water homeostasis
within the human body, and the increase of the plasma osmolality will trigger the release of
the AVP to the kidney to reabsorb water excreted from intracellular space. Since we induced
the increase of plasma osmolality of subjects in dehydrated trial by infusion of 3% saline, we
expected the rise of the AVP particularly in the dehydrated trial. Moreover, as previous
studies (Enhoning et al., 2013; Morgenthaler, Struck, Alonso & Bergmann, 2006; Saleem et
al., 2009) show that copeptin is a better surrogate to measure the AVP, therefore we measured
plasma copeptin instead of AVP. Our results show that plasma copeptin of the dehydrated trial
was significantly higher than that of the euhydrated trial, starting from the time point -90 min
till the end of the experiment. Since AVP released as soon as plasma osmolality increased, the
rise of first 2-hour 3% saline infusion corresponded with the well-defined AVP function,
which is water retention. During the OGTT period, the dehydrated trial still had a
significantly higher level of plasma copeptin than that of the euhydrated trial till the end of
the experiment. This result might suggest that after a 2-hour of dehydration, the ingestion of
glucose might still stimulate the increased release of the AVP in dehydrated trial compared to
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the euhydrated trial, since the ingestion of glucose might have further aggravated the
concentration of extracellular fluid, which induced the prolonged hypertonic state in fluid
compartments, the AVP rise in dehydrated trial was induced to alleviate the cellular
dehydration by directing the reabsorption of water in the kidney. Hence, it might safe to
conclude from this study that the ingestion of glucose might aggravate the cellular
dehydration following 2-hour dehydration period. This finding is relatively new compared to
a previous study (Taveau et al., 2014) that only examined the long-term relationship between
low water intake and high plasma copeptin level under hyperglycemia. Therefore, our results
support that the 3% saline infusion is able to increase the AVP secretion.
Serum insulin and fasting glucose. Contrary to the previous studies (Enhorning et
al., 2013; Vintila et al., 2016;), where significantly elevated levels of plasma osmolality,
plasma copeptin are strong indicators for the impaired glucose regulation in then healthy
human beings participated in the studies, our result of fasting plasma glucose show that there
was no significant difference between dehydrate trial and euhydrated trial. The reason might
have been that the subjects of our study are healthy females without diabetes symptoms, and
it was only a 6-hour trial with low water intake compared to those years long studies with
subjects having low water intake. Nonetheless, the level of fasting plasma glucose of
dehydrated trial was higher than that of the euhydrated trial without significanc in terms of
one-way ANOVA analysis. However, the analysis of area under the curve found that the
glucose levels were significantly higher in dehydrated trial than that of the euhydrate trial.As
for the level of serum insulin, there was a significant difference between two trials at the time
point 30 min, with euhydrated trial having a higher serum insulin level. Moreover, at time
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point 60 min, the difference between two trials nearly approached significant level. These
results might suggest that the glucose regulation was impaired in the dehydrated trial.

Limitations of the Study

The limitations of our study are that since it is human study, we cannot elaborate and
find mechanism behind the reason as animal studies do, and females with body fat higher
than 30% might have compounded the statistical analysis, as suggested by the study
(Anastasiou et al., 2010) that insulin sensitivity is adversely associated with the increase of
the body fat. Nevertheless, the specific topic and hypothesis our study investigated are
relatively new in the field, because previous similar studies were only done in males and
animals.

Conclusions and Future study

We might conclude from this study that hypertonic saline infusion impairs glucose
regulation in the healthy females.
Future study should investigate the reason why insulin was significantly higher at 30
min in the euhydrated trial under the same circumstance.
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